Study Onmesalazine Enteric-coated Microcapsule Capsules

The first-line therapy for chronic colitis is mesalazine.Mesalazine is frequently formulated into a colon-specific dosage form because it can be successfully treated by maintaining a high concentration in the intestinal cavity.Enteric microcapsules,a frequently employed method of colon-specific drug delivery,have the qualities of high safety and strong stability,and they can avoid gastric acid damage to achieve the effect of intestinal absorption.As a result,the use of enteric microcapsules in the therapy of intestinal diseases is crucial.This study created mesalazine into enteric microcapsules and systematically investigated it to enhance the therapeutic impact of mesalazine on ulcerative colitis,an intestinal disease.The first-line therapy for chronic colitis is mesalazine.Mesalazine is frequently formulated into a colon-specific dosage form because it can be successfully treated by maintaining a high concentration in the intestinal cavity.Enteric microcapsules,a frequently employed method of colon-specific drug delivery,have the qualities of high safety and strong stability,and they can avoid gastric acid damage to achieve the effect of intestinal absorption.As a result,the use of enteric microcapsules in the therapy of intestinal diseases is crucial.This study created mesalazine into enteric microcapsules and systematically investigated it to enhance the therapeutic impact of mesalazine on ulcerative colitis,an intestinal disease.The encapsulation rate and particle size of enteric microcapsules were investigated as the indexes for single-factor screening of the mesalazine enteric microcapsules process and prescription.Toidentify the best dosage of mesalazine enteric microcapsules,star-point design experiments were carried out,factors that had a significant impact on particle size and encapsulation rate were chosen,and a study of process reproducibility was completed.Mesalazine enteric microcapsule quality requirements were investigated.The quality standards of mesalazine enteric coated capsules including appearance,particle size,encapsulation rate,and in vitro release test were studied to create pharmaceutical formulations that satisfy the requirements of quality standards.Enteric capsules’ stability study revealed no appreciable changes in appearance or impurity content,suggesting the dosage form is stable.Rats’ in vivo intestinal absorption,tissue distribution,and performance of mesalazine enteric microencapsulated capsules in comparison to the regular formulation group were all investigated.The half-life of mesalazine enteric microcapsules was considerably longer than that of the regular formulation of mesalazine,indicating that mesalazine enteric microcapsules have a delayed release effect,according to the analysis of pharmacokinetic parameters in the pharmacokinetic experiments.The formulation of mesalazine enteric microcapsules is more effective for drug distribution in the colon when compared to mesalazine normal formulation in terms of tissue distribution.It may be observed that enteric microcapsules may be able to facilitate medication absorption by contrasting the in vivo intestinal absorption trials of mesalazine enteric microcapsules and mesalazine standard formulation.An experimental foundation for future studies of mesalazine microencapsulated formulations is provided by the pharmacokinetic study.